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Summary: Polyethylene glycol has been in use for a number of years for the assessment of gut permeability. The
methods so far employed are usually limited to polyethylene glycols in the low relative molecular mass r nge (up
to MT1300). We developed a method for the simultaneous determination of gut permeability to Mr400, Mr 1500,
Afr4000 and Mr 10000 polyethylene glycol, by applying a single oral dose of an appropriate mixture of these
polyethylene glycols. After extraction from 24 h-urine, MT1500, A/r4000 and MT10000 polyethylene glycol were
quantified by size exclusion chromatography, while Mr 400 polyethylene glycol was determined by reversed phase
chromatography. The detection limit of polyethylene glycol in the relative molecular mass r nge between Mr 1500
and Μτ 10000 was found to be 0.2 mg/1 urine, and the detection limit of Afr400 polyethylene glycol 5 mg/1 urine.
Recovery of the polyethylene glycols (N = 6) were 86.6% (CV: 4.8%) for H 400, 94.1% (CV: 7.2%) for Mr 1500,
97.1% (CV: 5.5%) for Mr4000 and 97.4% (CV: 5.6%) for Mr 10000.
No significant difference was found between the excretion rates in 24 h-urine of MT 400 and A/r 1500 polyethylene
glycols in patients with Crohn's disease (Λ/Γ400: 34.4 ± 5.5%; MT1500: 5.22 ± 2.27%; mean ± SEM, N = 10)
and healthy controls (Mr400: 33.6 ± 3.2%, Mr 1500: 1.09 ± 0.26%; N = 21). The excretion rate of Λ/Γ4000
polyethylene glycol was markedly higher in patients with Crohn's disease (0.462 ± 0.177%) than in healthy controls
(0.049 ± 0.012%, p < 0.05). MT10000 polyethylene glycol was detected in the urine of only one out of the 21
healthy controls, but in nine out of the ten patients with Crohn's disease (p < 0.001). These results suggest a change
not in number but rather in selectivity in permeability of high MT molecules.
Introduction 14C- or 3H-labelled organic compounds (8, 12) have
_- . - , t been used. Commonly used marker substances of highChanges m the permeability of the gut mucosa have . . . . ,, , . ~ . . . * , . relative molecular mass are polyethylene glycols m thebeen the object of increasing interest d nng recent ' \ rAA J ..' . . . i ", - - « r nge between Mr 400 and Mr 600 (13-19) or aroundyears, especially in patients with chromc inflammatory "
ι ι ι - ττ -i i 11 ,.1 J ^Γ 1«3UU (21) — 2Z).bowel diseases. Until now, almost all the compounds ·
used to measure the intestinal permeability have been of Thus, intestinal permeability has been measured with
low relative molecular mass (MT 180--Mr 380). These either only low-Afr substances, or one containing radio-
have been mannitol (1) and rhamnose (2), frequently in nuclides. A non-invasive test permitting the simulta-
comtynation with a disaccharide such s cellobiose (3, neous determination of human gut permeability to com-
4) or lactulose (5-7). In many cases, radioactive sub- pounds in both the low and high relative molecular mass
stances such s 51Cr-EDTA (8-10), "Tc-DTPA (11), r nge not containing radioactive components would be
desirable.
') This study was supported by the Robert.Bosch-Stiftung (grant ™* ideal substance must be neither toxic nor metabo-
F2). Used by either man or the intestinal flora. Polyethylene
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glycol meets all these demands (18), but its poor separa-
bility by reversed phase high performance liquid chro-
matography (RP-HPLC), and its unsatisfactory volatibil-
ity in gas chromatography have so far limited its use to
the maximum relative molecular mass of Mr 1300 (18,
20, 23, 24-26). With the exception of polyethylene gly-
col MT 3000 and MT 4000, which were determined by
open gel chromatography (27-29) or by a turbidimetric
procedure (30), no high Mr polyethylene glycols have
been used s markers in the systematic assessment of
permeabiiity in man to our knowledge.
In this study, measurement of the simultaneous absorp-
tion of the four Mr 400, MT1500, Mr 4000 and Μτ 10 000
polyethylene glycols has been made possible by opti-
mizing the percentage of each relative molecular mass
r nge in one orally administered mixture. The method
was tested for reproducibility and applicability. The per-
meabiiity measured in a group of patients with Crohn's
disease (N = 10) was compared with that of a group of
healthy Qpntrols (N = 21).
Materials and Methods
Reagents and Instrumentation
Chloroform p.a., methanol p.a. and Λ/Γ 400, MT 4000, Mv 10000
polyethylene glycols were purchased from Merck, Darmstadt, Ger-
many. A/r 1500 polyethylene glycol was obtained from Serva, Hei-
delberg, Germany. Teflon filters (0.45 μηι) were supplied by Al-
drich, Steinheim, Germany.
All solvents were removed in a vacuum centrifuge (Bachhofer,
Reutlingen, Germany). The Separation was carried out on a semi-
preparative column (500 mm X 8 mm), fllled with Lichrospher
Diol 5 μηι 100 (Merck, Darmstadt). This column was protected
by a pre-column (20 mm x 4 mm), fllled with the same material.
Mr 400 polyethylene glycol was separated on a column (250
mm X 4 mm) containing Nucleosil 7C8 (Macherey-Nagel, D ren,
Germany). All polyethylene glycol fractions were quantified by
measuring the differential refraction index (type ERMA 7512,
ERC, Alteglofsheim, Germany). The Signals of this detector were
evaluated by an Integrator (type 2000 D, Merck, Darmstadt, Ger-
many).
Polyethylene glycol application and extraction
Each test subject ingested 2 g Mr 400, l .5 g H 1500, 5 g Mr 4000
and 10 g Mr 10000 polyethylene glycol, all dissolved together in
100 ml of water; this solution was given s a drink after breakfast.
Urine was collected during the next 24 hours. Hundred ml of the
homogenised urine were stored at —20 °C and analysed within 6
months. For analysis, two 45 ml volumes of the urine were centri-
fuged for 10 minutes at 1000g. Clear supernatant (40.0 ml) was
extracted with 3.0 ml Chloroform by vigorous shaking (2 min). The
lowest, emulsified, chloroform/urine layer was transferred into cen-
trifugation tubes. The urine was extracted once more with 2.0 ml
Chloroform. After centrifugation, the two chlorof rm/urine emul·
sions were combined. The supernatant urine was used for determi-
nation of Mr 400 polyethylene glycol.
water. After rernoval of water, the remaining Chloroform layer was
weighed. The loss of polyethylene glycol during the extraction pro-
cedure was determined by calculating the final volume of Chloro-
form against the Start volume. The Mr 1500, Mr 4000 and Mr 10 000
polyethylene glycols remaining in the residue after evaporation of
Chloroform were extracted with 400 μΐ of HPLC solvent (methanol/
water, 66 + 34, by vol.) for ten minutes in an ultrasonic bath
(50 °C). The resulting Suspension, was filtered through a teflon
membrane fllter (0.45 μηι) and 200 μΐ of this solution were applied
to the HPLC at a flow rate of l ml/min (method A).
Reversed phase chromatography of Mr 400
polyethylene glycol
Four ml of the urine, remaining after extraction with Chloroform,
were evaporated. For complete dissolutiori of Mr 400 polyethylene
glycol, the residue was extracted with l ml of methanol in an ultra-
sonic bath at 50 °C for 30 min and centrifiiged (2500 g for 5 min).
Fivehundred μΐ of the clear supernatant were evaporated to dryness
and the residue redissolved in 400 μΐ mobile phase (methanol/water
20 + 80, by vol.). Hundred μΐ of this solution were quantified by
reversed phase chromatography (Nucleosil 7C8, l ml/min, method
B, modification of a method described in 1. c. (24)). To minimize
difficulties during the determination of Mf 400 polyethylene glycol
(fig. 6), peak area of the Mr 418 compound (26.09 min) was used
for calculation of Mr 400 permeabiiity. This compound has shown
the lowest inteiference with the initial background peak arid the
lowest difference to the theoretical relative molecular mass ratio
MT 400. Recovery was calculated s the quotient of the peak area
of the urine-extracted compound and the peak area of the fraction
in Standard solution, directly employed in HPLC.
Patients and healthy volunteers
To test the applicability of this procedure, the permeabiiity of the
gut to all four polyethylene glycol molecular weight fractions was
determined in a group of healthy controls (N = 21) and a group of
patients with Crohn^s disease (N = 10). The diagnosis of Crohn's
disease was con rrned by X-ray and/or endoscopy findings. The
average Crohn's disease activity index (CDAI s reported by Beck
(31)) of the patients with GO/W'S disease was 140 ±21. None of
the patients had undergone resection; their average age was 39.7
± 4.4 years and their average body weight 70.2 ± 7.7 kg (mean
± SEM).
The members of the control group did not differ from those of the
patient group in either age (37.0 ± 2.9 a) or weight (72.0 ± 4.34
kg), nor was there any difference in sex distribution. Creatinine
clearance was normal in all subjects.
Mass ratio of ingested MT 400, MT 1500, Mr 4000 and
Λ/Γ 10000 polyethylene glycols
The mass ratios of the different polyethylene glycols in the mixture
employed were optimized in such a way s to obtain cornparable
concentrations of Mt 1500, Mr 4000 and Mr 10000 polyefhylene
glycol in the urine samples. In this way it was possible to quantify
these three fractions in a single Chromatographie analysis. The
arnount of MT10000 polyethylene glycol employed was limited to
10.0 g because of the laxative effect of this compound. The in-
gested amount of Mr 400 polyethylene glycol was four times. s
large s Mr 1500 polyethylene glycol beeause a less sensitive
method of analysis was used.
Size exclusion chromatography of MT 1500, Μτ 4000
and Mr 10000 polyethylene glycol
The chloroform/urine emulsion was centrifuged (2500 g, 20 min at
4 °C) and the clear Chloroform layer washed twice with distilled
Calibration, linearity, reproducibility, recovery,
stability and detection limits
Before polyethylene glycol ingestion, urines of both groups were
checked for the appearanee of disWbing peaks in the chromato-
Eur. J, Clin. Chem. Clin. Biochem. / Vol. 32, 1994 /Np. 11
Parlesak and Bode: Gut permeability of Mr 400, Mr 1500, Mr 4000 and Mr 10000 polyethylene glycoi in man 815
grams at coincident retention times. The pooled polyethylene gly-
col stock solution in urine had the following concentration; Mr 400:
2.0 g/I; A/r 1500: 500 mg/1; MT 4000: 200 mg/1 and Afr 10000: 20
mg/1. This solution was diluted with urine l : 2, l : 4, l : 10, l : 50,
l : 100 and l : 200. These diluted Standard Solutions were appor-
tioned, stored at —20 °C, and used for the determination of calibra-
tion curves, reproducibility, stability and detection limits. Recovery
after extraction frorn urine was determined by calculating the peak
area of each polyethylene glycoi fraction against the peak area of
Standard Solutions dissolved in the appropriate mobile phase. Re-
producibility and stability were checked in aliquots over a period
of six months.
Statistics
All results are indicated s mean values ± Standard error of mean
(X ± SEM). Wilccxon^s rank surh test was used to assess signifi-
cances between the two groups. Results obtained measuring the
permeability of Mr 10000 polyethylene glycoi were not suitable
for Wilcoxon's rank sum test, because no Mr 10000 polyethylene
was detected in the control group in 9 out of 10 urines. These
results were compared by the x2-test.
Results
Chromatographie Separation and extraction of
different polyethylene glycoi fractions
Organic biopolymers, usual matrices for Separation of
constituents according to their relative molecular mass,
showed after a few Chromatographie runs with samples
gained by the described procedure a fast increase in
pressure over the maximum limit. Because of its poros-
ity (about 100 ) and its pressure stability, semipolar
reversed phase material (Diol) proved highly suitable for
size exclusion chromatography, when all attraction phe-
nomena of polyethylene glycoi to the stationary phase
were suppressed. In an attempt to find the best mobile
phase, the methanol/water solvent was optimized. Figure
l shows the Separation of the four polyethylene glycol-
fractions of the methanol/water ratio. The capacity
factor k1 was used s a me sure of Separation. The ca-
pacity factor k1 is defiried s
k' =
where tr is the retentiori tirne of the analysed molecule
fraction and tn, the retention time of a non-retarded
solvent molecule since injection.
The capacity factors of the four polyethylene glycoi MT
fractions employed were measured with four different
compositions of the mobile phase. A regression analysis
of these results (polynome, second grade) was made to
identify the optimal point of Separation for all four poly-







0.0 0.2 0.4 0.6 0.8 1.0
Methanol, volume fraction
Fig. l Capacity factor k1 of four polyethylene glycoi fractions (O:
MT 400, O: 1500, +: Mr 4000 and D: Mr 10000) on a Lichrospher
Diol 5 μ column (500 mm X 8 mm, flow: l ml/min) s a function
of the volume fraction of methanol in mixture with water.
the approximated function (fig. 1). Optimal conditions
were found to differ for each MT fraction, ranging
from 54 + 46 (methanol/water) for Mr 400 polyethyl-
ene glycoi to 68 + 32 for A/r 10000 polyethylene
glycoi. Satisfactory simultaneous Separation of all four
fractions was obtained at a mixture of 66 + 34. Under
these conditions, there was no increase in pressure
over more than 100 runs with samples gained by the
described procedure.
Under the given conditions of Chloroform extraction,
migration of Μτ 400 polyethylene glycoi from the urine
into the organic layer was below the detection limit. This
lack of extractability of Μτ 400 polyethylene glycoi
made a separate analysis necessary. Mr 1500, Μτ 4000
and M,. 10000 polyethylene glycoi, on the other hand,
were emiched completely in the Chloroform layer by
twofold extraction of the organic solvent. A third Chloro-
form extraction contained no detectable traces of any of
this three polyethylene glycoi fractions.
No disturbing Signals at relevant retention times for Mr
1500, A/r 4000 and Mr 10000 polyethylene glycoi were
obtained after extraction (method A) of urines contain-
ing no polyethylene glycoi (fig. 2). Figure 3 shows the
chromatogram of an evaporated Chloroform extract of a
urine stocked with 500 mg/1 of each of the four polyeth-
ylene glycoi fractions. A chromatogram of a Standard
solution of MT 400 polyethylene glycoi (2 g/l) is shown
in figure 4. Urine without polyethylene glycoi showed
no disturbing peaks at the retention time of Afr 418 (fig.
5). After oral administration of the described polyethyl-
ene glycoi mixture, the content of Afr 400 polyethylene
glycoi in the excreted urine could be quantified (fig. 6).
Permeability of A/r 400 polyethylene glycoi was calcu-
lated s the permeability of Mr 418 polyethylene glycoi
(26.09 min in fig. 6).
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Fig. 2 Chromatogram of an evaporated Chloroform extract
(method A) from a urine without polyethylene glycol; Peak
at 20.12 min resulting from urine matrix. Mobile phase: metha-
nol/vvater 66 -l- 34, by vol.; flow: l ml/min; sample volume:




Fig. 3 Chromatogram of an evaporated Chloroform extract
(method A) from urine; the urine was spiked with 500 rhg/1 each
of Mr 400, Mr 1500 (14.9 min), Mr 4000 (12.5 min) and Mt 10000
(10.1 min) polyethylene glycol. Peak at 20.00 min resulting from
urine matrix. Mobile phase: methan l/water 66 + 34, by vol.; flow:
l ml/min; sample volume: 200 μΐ.
The detection limit of method A, defmed by a signal-to-
noise-ratio of 5 : l, was determined for MT 1500, Μτ
4000 and MT 10000 polyethylene glycol to be 0.2 mg/1
each. The detection limit for method B (A/r 400 polyeth-
ylene glycol) was 5 mg/1, which reflected the lower en-
richment of polyethylene glycol by this method. The re-
covery of polyethylene glycols (N = 6) in frozen urine
measured on different days was 86.6% (CV: 4.8%) for
Mr 400, 94.1% (CV: 7.2%) for MT 1500, 97.1% (CV:
5.5%) for Mr 4000 and 97.4% (CV: 5.6%) for Mr 10 000.
The amount of polyethylene glycol proved to remain
stable over a storage time of up to six months.
Permeabil i ty in pat ients with Crohn's disease
and in healthy controls
The excretion of MT 400 polyethylene glycol by patients
with Crohn's disease (34.4 ± 5.5%, mean ± SEM) did
not differ from that in the control group (33.6 ± 3.2%).
There was also no difference of the relative amount of
Mr 1500 polyethylene glycol in the permeated urine in
patients with Crohn's disease (5.22 ± 2.27%) s com-
pared with that of the healthy controls (1.09 ± 0.26%,
0.05 < p < 0.10). The excretion of MT 4000 polyethyl-
ene glycol was significantly higher in patients with
C/O/W'S disease (0.462 ± 0.177%) than in the control
group (0.049 ± 0.012%, p < 0.05). Mr 10000 polyeth-
ylene glycol was detectable in the urine in only one of
the 21 healthy controls (detection limit at 0.2 mg/1), but
in nine of the patients with Crohn's disease (0.229
± 0.070%o, p < 0.001).
With the employed amounts of polyethylene glycols,
laxative effects were neither observed in the group of
patients with Crohn's disease nor in that of healthy vol-
unteers. This fact corresponds well with results pub-
lished by other authors (18, 19, 21, 23).
Discussion
Polyethylene glycol was first used s a marker for rnea-
suring the permeability of the gut by Chadwick (18).
Several other authors recognized the importance of the
relative molecular mass of this permeability marker, but
due to analytical eonstraints employed a maximal rela^
tive molecular mass of only Mr 1300 (20, 23-26). Poly-
ethylene glycol, having a relative molecular mass of up
to MT 4000, was employed in only two studies, and ana-
lysed with the time-consuming open gel chromat gra-
phy (27, 28). The new method described readily allows
the simultaneous deterrnination of gut permeability to
polyethylene glycols ranging from Mr 400 to Μτ 10000
ingested simultaneously. Due to the urine sampling tirne
(24 h), this procedure may serve to assess the overall
permeability of compounds over a wide relative molecu-
lar mass r nge from the whole intestine into the systemic
blood stream.
Poor pressure stability of the gel· colurnns and the possi-
bility of microbiological degradation rn ke it difflcult to
work with those organic polymers often used s a Sepa-
ration matrix for size exclusjibn chromatography. Silica,
Bur. J. Clin. Chem. Clin. Biochem. / Vol. 32,1994 / No. «11
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Fig. 4 Chromatogram of a Standard solution of Mr 400 polyeth-
ylene glycol (0.1 g/l). Mobile phase: methanol/water 20 + 80,
by vol.; flow: l ml/min; sample volume: 100 μΐ. Single peaks
are: 9.23 min: Afr 286; 12.73 min: Mr 330; 18.24 min: Mr 374;
26.86 min: Mv 418 polyethylene glycol.
o 10 20 30
Retention time [min]
Fig. 5 Chromatogram of a methanolic extract (method B) of urine
from a patient with Crohn's disease without pojyethylene glycol
(method A). Mobile phase: methanol/water 20 + 80, by vol.; flow:
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Fig. 6 Chromatogram of a methanolic extract (method B) of urine
from the same patient with Crohn's disease mentioned in figure
5 after ingestion of polyethylene glycol mixture. Mobile phase:
methanol/water 20 + 80, by vol.; flow: l ml/min; sample volume:
100 μΐ. Single peaks are: 4.51 min and 7.23 min: initial background
peaks; 9.05 min: Mt 286; 12.61 min: Mr 330; 18.24 min: M, 374;













Fig. 7 Correlation between relative excretion of ingested MT 400,
Mr 1500, MT 4000 and A/r 10000 polyethylene glycol and the mo-
lecular diameter, expressed s the cube root of the relative molecu-
lar mass A/D in healthy controls (o, N = 21) and in patients with
Crohn's disease (O, N = 10). Vertical bars indicate SEM.
which does not have these disadvantages, is porous not
only in its natural, but also in a modified state. This
porosity makes it suitable for size exclusion chromato-
graphy. To obtain a r nge for optimization of the
solvent, a semipolar Diol-phase was used s stationary
phase. In order to be able to utilize the size exclusion
effects, the strength of the mobile phase was adjusted
so s to suppress all surface (adsoφtion and reverse
phase) effects.
Mixtures of acetone, cetonitrile, tetrahydrofuran and
methanol with water were all suitable for Separation of
Eur. J. Clin. Chem. Oin. Biochem,/Vol. 32,1994 /No. 11
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the polyethylene glycol fractions, but the mobile phase
used was optimized with methanol äs the organic com-
ponent (flg. 1), resulting in high detection limits, reflect-
ing the low refraction index of methanol.
Because of confounding elements in the urine, a method
for the determination of MT 400 polyethylene glycol by
reversed phase-HPLC developed earlier (24), had to be
modified.
Some authors have used MT 400 polyethylene glycol for
determination of gut permeability under comparable
conditions (16, 19, 24, 32). Their results correspond
well, in terms of order of magnitude, with the values
determined in this study, although the amount of MT 400
polyethylene glycol ingested was considerably higher
(up to 5 times) than in the present study. Thus, the up-
take and excretion of Mr 400 polyethylene glycol does
not seem to correlate with the amount ingested.
The use of polyethylene glycol fractions with a mölecu-
lar weight of between Mr 400 and Mr 1300 äs permeabil-
ity markers resulted in the detection of 20—50% of the
ingested polyethylene glycol in the urine, even in per-
sons with no signs of any bowel disease (14—16, 19,
21, 33). Among others, the high excretion rate of
ingested polyethylene glycol may be the reason for
the contradictory results obtained when comparing per-
meability in patients with Crohn's disease and in heal-
thy controls — the permeability to polyethylene glycol
of less than Mr 1300 in the patients was found to be
comparable (16, 19), higher (14, 33) or lower (15, 21)
than in controis.
The importance of employing polyethylene glycols with
MT > 1500 is underscored by comparing the renal excre-
tions of Mr 4000 and MT 10000 polyethylene glycol in
patients with Crohn's disease and in healthy controls.
The excretion of 4000 polyethylene glycol in the pa-
tients was found to be ten times äs high äs in the con-
trols. 10000 polyethylene glycol was detected in the
urine of only one out of 21 persons in the control group,
but in that of nine out of ten in the Crohn's disease
group.
When using polyethylene glycol to investigate changes
in intestinal permeability relating to certain bowel dis-
eases, it may be important to be aware of the signifi-
cance of the MT of polyethylene glycol used. A decisive
factor for the permeation of any compound through the
epithelium of the mucosal barrier in the gut is the spatial
extent of the molecule. The average diameter of this
molecule is directly related to the cübe root of relative
molecular mass. In any case, the correlation between
the diameter and the cube root of the relative molecu-
lar rnass does not depend on the exact shape of the
molecule. Doubling the average diameter of a mole·̂
cule requires an eight-fold increase in molecular mass.
A search for the mathematical function best able to ex-
press the correlation between the diameter of the mole-
cule and excretion showed the best ernpiric approxima-
tion to be the exponentional one:
relative excretion ~ b (*PlecuIar diameter)
and, thus,
relative excretion ~ b(> ) ,
where b is the basis of the exponential function and Mr
the relative molecular mass of the permeating molecule.
This proportionality can also be expressed äs an equa-
tion by introducing the proportionality factor k:
relative excretion = k · b r ) .
Figure 7 shows the very good linearity of this coitelation
in both the healthy controls (r = 0.9973) and the patients
with Crohn's disease (r = 0.9990). The relative perme-
ability clearly decreases more rapidly with increasing
molecular diameter (expressed äs the eube root of rela-
tive molecular mass) in the controis äs compared with
that of patients with Crohn's disease.
The respective values calculated from permeability
means of both groups for b and k were 0.595 and 1750
in patients with Crohn's disease, and 0.464 and 8620 in
healthy controls. In the above equation, the chänge in
gut permeability is expressed mainly by the variable
b. A rapid chänge in permeability with increasing MT
results in only a slight chänge of b. This slow chänge
of b is caused by the high expoiient, which is a
function of the relative molecular mass. Therefore a
slight chänge in b signifies a clear chänge in perme-
ability. Means for b are 0.579 ±0.019 for the patient
group and 0.423 ±0.019 for the group of healthy
controls (p < 0.001).
Further investigations will be needed to show whether
the parameters of the äböve regressed equation (espe-
ciälly b) can serve äs factors for the assessment of in-
flammatory bowel diseases.
Figure 7 shows that, äs compared with healthy controls,
the percentage permeability in patients with Crohn's dis-
ease was changed only slightly in the low, but markedly
in the high molecular ränge. This may suggest an ältered
selectivity of leaky places in the mucosal gut barrier
räther than a chänge in their number.
The determination of permeability of high Mr com-
pounds in other intestinal disjEjases might also be impor-
Eur. J. Clin. Chem. Clin. Biocherh. / VoL 32,1994/No. 11
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tant because of their potentially antigenic efFects. When
investigating the relative molecular mass distribution of
endotoxins in human feces, for example, we were able
to identify endotoxins ranging between A/r 1500 and Mr
25 000 (34). The fact that this ränge overlaps with that
of the polyethylene glycol used in the present study
(A/r 400—Mr 10000) underscores the importance of
measuring permeability in the high-Mr ränge.
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